Lyell Immunopharma, Inc. (LYEL)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
13.40 USD
-0.93
(-6.490%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:57 a.m. EDT
The investment case for Lyell Immunopharma is currently nonexistent due to a catastrophic multi-year structural decline. The company has suffered four consecutive years of negative annual returns, with the stock down nearly 97% over the last four years. Fundamentals are severely impaired: the business is burning cash aggressively with negative free cash flow, operating losses that dwarf revenue, and a shrinking top line. While the balance sheet remains technically solvent with significant cash reserves relative to debt, the relentless price destruction suggests the market has priced out any hope of a turnaround in the near term. The recent price action shows a slight stabilization after a sharp drop, but the technicals remain deeply bearish, trading well below both the 50-day and 200-day moving averages. Options activity confirms this pessimism, with traders loading up on cheap put protection rather than betting on a recovery. Until there is concrete evidence of a clinical inflection point translating into revenue growth and a halt to the cash burn, this remains a high-risk speculative vehicle with no margin of safety. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.312694 |
| AutoETS | 0.352734 |
| AutoARIMA | 0.352892 |
| MSTL_74 | 0.353777 |
| MSTL | 0.358011 |
| MSTL_105 | 0.463409 |
| MSTL_74_105 | 0.467852 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 24.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.138 |
| Excess Kurtosis | -1.24 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 17.851 |
| Revenue per Share | 0.002 |
| Market Cap | 312,676,768 |
| Forward P/E | -15.95 |
| Beta | -0.06 |
| Website | https://www.lyell.com |
As of July 11, 2026, 4:57 a.m. EDT: Speculators are overwhelmingly positioning for downside protection, evidenced by massive open interest in out-of-the-money puts compared to negligible call activity. The July expiration shows heavy put volume and open interest at the money and slightly out-of-the-money strikes, while call open interest is concentrated deep in-the-money, suggesting a 'bear put spread' or hedging strategy rather than a bullish bet. Implied volatility is extremely low (near zero for many strikes), indicating a lack of speculative premium pricing for upside moves and a market consensus expecting stagnation or further decline.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4060861 |
| Address1 | 201 Haskins Way |
| Address2 | Suite 101 |
| All Time High | 396.8 |
| All Time Low | 7.65 |
| Ask | 17.02 |
| Ask Size | 2 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 206,130 |
| Average Daily Volume3 Month | 147,847 |
| Average Volume | 147,847 |
| Average Volume10Days | 206,130 |
| Beta | -0.062 |
| Bid | 10.01 |
| Bid Size | 2 |
| Book Value | 11.731 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.4 |
| Current Ratio | 7.235 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 14.24 |
| Day Low | 13.23 |
| Debt To Equity | 17.851 |
| Display Name | Lyell Immunopharma |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -176,040,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.611 |
| Enterprise To Revenue | 3,467.896 |
| Enterprise Value | 107,504,768 |
| Eps Forward | -0.84 |
| Eps Trailing Twelve Months | -13.62 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.4814 |
| Fifty Day Average Change | -2.0814 |
| Fifty Day Average Change Percent | -0.1344452 |
| Fifty Two Week Change Percent | 40.60861 |
| Fifty Two Week High | 45.0 |
| Fifty Two Week High Change | -31.6 |
| Fifty Two Week High Change Percent | -0.7022222 |
| Fifty Two Week Low | 9.11 |
| Fifty Two Week Low Change | 4.29 |
| Fifty Two Week Low Change Percent | 0.4709111 |
| Fifty Two Week Range | 9.11 - 45.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,623,936,600,000 |
| Float Shares | 9,621,111 |
| Forward Eps | -0.84 |
| Forward P E | -15.952381 |
| Free Cashflow | -77,380,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 161 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 31,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.39516 |
| Held Percent Institutions | 0.56832004 |
| Implied Shares Outstanding | 23,334,087 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-17 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,748,822,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. |
| Long Name | Lyell Immunopharma, Inc. |
| Market | us_market |
| Market Cap | 312,676,768 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_590661061 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -246,406,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 328,848,484 |
| Number Of Analyst Opinions | 6 |
| Open | 14.24 |
| Operating Cashflow | -133,796,000 |
| Operating Margins | -22,130.5 |
| Payout Ratio | 0.0 |
| Phone | 650 695 0677 |
| Previous Close | 14.33 |
| Price Hint | 2 |
| Price To Book | 1.1422726 |
| Price To Sales Trailing12 Months | 10,086.348 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.875 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | -0.93 |
| Regular Market Change Percent | -6.48988 |
| Regular Market Day High | 14.24 |
| Regular Market Day Low | 13.23 |
| Regular Market Day Range | 13.23 - 14.24 |
| Regular Market Open | 14.24 |
| Regular Market Previous Close | 14.33 |
| Regular Market Price | 13.4 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 171,278 |
| Return On Assets | -0.29867 |
| Return On Equity | -0.80764 |
| Revenue Growth | -0.714 |
| Revenue Per Share | 0.002 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,334,087 |
| Shares Percent Shares Out | 0.052399997 |
| Shares Short | 1,223,220 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,353,275 |
| Short Name | Lyell Immunopharma, Inc. |
| Short Percent Of Float | 0.0617 |
| Short Ratio | 5.02 |
| Source Interval | 15 |
| State | CA |
| Symbol | LYEL |
| Target High Price | 49.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 37.16667 |
| Target Median Price | 41.5 |
| Total Cash | 254,023,008 |
| Total Cash Per Share | 10.886 |
| Total Debt | 48,851,000 |
| Total Revenue | 31,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -13.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.83755 |
| Two Hundred Day Average Change | -7.4375496 |
| Two Hundred Day Average Change Percent | -0.35693014 |
| Type Disp | Equity |
| Volume | 171,278 |
| Website | https://www.lyell.com |
| Zip | 94,080 |